Skip to main content
ELOX
NASDAQ Life Sciences

10% Owner Converts $7.2M in Pre-Funded Warrants to Common Stock at 50% Discount

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$12
Mkt Cap
$587.127K
52W Low
$0.023
52W High
$17.5
52W Position
Off High info
31% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

Summary

Domicilium Real Estate Fund III LP, a 10% owner, converted $7.2 million worth of pre-funded warrants into 1,200,000 common shares at an implied price of $6.00 per share, a 50% discount to the current market price.


Key Events · Ownership and Investor Activity · ELOX

  • Warrant Conversion

    Domicilium Real Estate Fund III LP, a 10% owner, converted pre-funded warrants into 1,200,000 shares of common stock on June 10, 2026.

  • Significant Value & Dilution

    The converted shares represent a value of $7.2 million, equivalent to approximately $6.00 per share, which is a 50% discount to the current market price. This conversion adds a substantial number of shares to the outstanding float.

  • Insider Ownership Change

    This transaction increases the 10% owner's direct holdings of common stock to 834,489 shares, following recent public offerings that included pre-funded warrants.


Analysis · ELOX · Life Sciences

This Form 4 reports that Domicilium Real Estate Fund III LP, a 10% owner, converted pre-funded warrants into 1,200,000 shares of common stock on June 10, 2026. This transaction, valued at $7.2 million, is a mechanical conversion of previously acquired derivative securities rather than an open-market purchase. The implied conversion price of approximately $6.00 per share is at a significant 50% discount to the current market price of $12.00. This event follows recent public offerings by Eloxx Pharmaceuticals that included pre-funded warrants, indicating the conversion of these instruments into common shares. While it increases the insider's direct common stock holdings, it also adds a substantial number of shares to the outstanding float, which is dilutive for existing shareholders.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELOX was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587.1K. The 52-week trading range was $0.02 to $17.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELOX - Latest Insights

ELOX
Aug 12, 2026, 6:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $15.31 info
Change: -$3.87 (-20%) info
Market Cap: $61.798M info
ELOX
Aug 11, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $15.31 info
Change: -$3.87 (-20%) info
Market Cap: $61.798M info
ELOX
Aug 11, 2026, 5:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $15.31 info
Change: -$3.87 (-20%) info
Market Cap: $61.798M info
ELOX
Jun 04, 2026, 5:17 PM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.370
Real-time Price: $15.31 info
Change: +$14.94 (+4,038%) info
Market Cap: $61.798M info
ELOX
Jun 01, 2026, 4:55 PM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.370
Real-time Price: $15.31 info
Change: Reverse Stock Split info
Market Cap: $61.798M info